Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limitations of spectrophotometry in the analysis of cerebrospinal fluid bilirubin.

Annals of clinical biochemistry·2026
Same author

Profiling Protein Aggregate Size Using Single-Molecule Array Technology.

Analytical chemistry·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Plasma proteomic signatures of cellular aging predict human disease.

Nature medicine·2026
Same author

Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Factors influencing implementation of an Alzheimer's disease blood test among UK old age psychiatrists: mixed-methods study using the theoretical domains framework.

Age and ageing·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Ashvini Keshavan1, Katharine Wiltshire2, Melanie Hart3,4

  • 1Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Plasma p-tau217 assays show high accuracy for Alzheimer's disease (AD) diagnosis. The Lumipulse assay demonstrated superior negative predictive value compared to ALZpath, supporting its use in clinical trials.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • The ADAPT study investigates plasma p-tau217's impact on Alzheimer's disease (AD) diagnosis and outcomes.
  • Stage 1 validated p-tau217 assays against cerebrospinal fluid (CSF) AD biomarkers and amyloid PET status.

Purpose of the Study:

  • To validate two commercial plasma p-tau217 assays (Lumipulse and ALZpath) against CSF AD biomarkers.
  • To derive and evaluate clinical cut-points for plasma p-tau217 assays.
  • To assess assay performance in an independent amyloid PET cohort.

Main Methods:

  • Plasma samples from CSF and amyloid PET cohorts were tested using Lumipulse and ALZpath assays.
  • Cut-points for 95% sensitivity and specificity were derived from the CSF cohort.
  • Assay performance metrics, including intermediate results, NPV, and PPV, were evaluated in both cohorts.

Main Results:

  • The CSF cohort (n=257) showed Lumipulse cut-points yielding 91% NPV and 96% PPV.
  • The amyloid PET cohort (n=76) showed Lumipulse cut-points yielding 89% NPV and 91% PPV.
  • Lumipulse demonstrated higher NPV than ALZpath across both cohorts, with 19-34% intermediate results.

Conclusions:

  • Lumipulse plasma p-tau217 assay accuracy exceeded 90% for high/low values in both cohorts.
  • Lumipulse showed superior NPV compared to ALZpath.
  • Validated Lumipulse cut-points will be used in a randomized controlled trial for result disclosure.